Document is current
Any future updates will be listed below
-
Authors
Ellis, Anne K.
Fleischer, David M.
Camargo, Carlos A. Jr.
Lowenthal, Richard
Tanimoto, Sarina
-
Funding
Funding for this research was provided by:
ARS Pharmaceuticals
- License Information
-
More Information
Article History
Received: 10 December 2025
Accepted: 24 April 2026
First Online: 7 May 2026
Declarations
:
: AK Ellis reports advisory boards for ALK-Abello, AstraZeneca, Bausch Health, Biocryst, Celltrion, Lilly, Novartis, Sanofi and Regeneron; speakers’ bureaus for ALK-Abello, AstraZeneca, Bausch Health, Biocryst, Celltrion, GSK, Medexus, Novartis, Sanofi and Regeneron; research support (paid to institution) from ALK-Abello, AstraZeneca, Bayer LLC, Medexus, Novartis, Sanofi and Regeneron; independent consultant to Bayer LLC and Regeneron; and royalties from UpToDate. She reports serving as a consultant and/or advisor for ARS Pharmaceuticals. DM Fleischer reports grants from ARS Pharmaceuticals and grants and consultant fees from DBV Technologies and serving as consultant/advisor for ARS Pharmaceuticals, Aquestive Therapeutics and for Bryn Pharma. CA Camargo, Jr. reports serving as consultant/advisor for ALK-Abello, ARS Pharmaceuticals, Bryn Pharma, and Aquestive Therapeutics. R Lowenthal and S Tanimoto are employed by ARS Pharmaceuticals Operations, San Diego, CA, USA.
